Login / Signup

Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer.

Namhee YuMihwa HwangYoungjoo LeeBo Ram SongEun Hye KangHanna SimBeung-Chul AhnKum Hui HwangJihyun KimSehwa HongSunshin KimCharny ParkJi-Youn Han
Published in: Journal of experimental & clinical cancer research : CR (2023)
Our PDC models recapitulated the molecular characteristics of lung cancer, and pharmacogenomics analysis provided plausible therapeutic candidates.
Keyphrases
  • clinical decision support
  • single cell
  • small molecule
  • cell therapy
  • emergency department
  • adverse drug